| Identification | |
| Name: | 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine,8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]- |
| Synonyms: | Rupatadine;8-Chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridyl)methyl)-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine;UNII-2AE8M83G3E; |
| CAS: | 158876-82-5 |
| Molecular Formula: | C26H26ClN3 |
| Molecular Weight: | 415.96 |
| InChI: | InChI=1/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3 |
| Molecular Structure: |  |
| Properties | |
| Flash Point: | 308.4°C |
| Boiling Point: | 586.4°Cat760mmHg |
| Density: | 1.233g/cm3 |
| Appearance: | off-white powder |
| Specification: |
The efficacy of Rupatadine (CAS NO. 158876-82-5 ) as treatment for allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) has been investigated in adults and adolescents (aged over 12 years) in several controlled studies, showing a rapid onset of action and a good safety profile even in prolonged treatment periods of a year. |
| Flash Point: | 308.4°C |
| Usage: |
Rupatadine (CAS NO. 158876-82-5 ) is a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. |
| Safety Data | |
 |
|
